ArticleThe World Allergy Organization journal2021
Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital.
Article in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Prick tests and basophil activation tests in hypersensitivity to SARS-CoV-2 vaccines and components.Allergologie select · 2026Article
- [Vaccination approach in patients with an allergic reaction to COVID-19 vaccines or at risk of developing allergic reactions].Tuberkuloz ve toraks · 2023Article
- Article
- Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions.Vaccines · 2023Article
- COVID-19 vaccine provocation test outcome in high-risk allergic patients: A retrospective study from a tertiary hospital in Indonesia.The World Allergy Organization journal · 2023Article
- Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions.Journal of the National Medical Association · 2022Review
- PEG allergy - A COVID-19 pandemic-made problem? A German perspective.The World Allergy Organization journal · 2022Article
- Successful fractionated undiluted doses of COVID-19 vaccine in five cases of suspected allergic reactions to the first dose.Clinical case reports · 2022Article
- Successful mRNA COVID-19 Vaccination and Colonoscopy After Oral Desensitization in a Patient With Polyethylene Glycol Allergy.Journal of Korean medical science · 2022Article
- Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis.Allergy · 2022Article
- Allergological study in patients vaccinated against COVID-19 with suspected allergic reactions.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication.Vaccines · 2022Article
- Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination-a narrative review.Wiener medizinische Wochenschrift (1946) · 2022Review
- Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.Vaccine · 2022Article
- CoronaVac/Sinovac COVID-19 Vaccine-Related Hypersensitivity Reactions and Second-Dose Vaccine Administration: Tertiary Allergy Center Experience.International archives of allergy and immunology · 2022Article
- Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose.Frontiers in allergy · 2022Article
- Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines.International archives of allergy and immunology · 2022Article
- Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases.Vaccines · 2021Review
- A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology.JAAD case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been approved recently, and public concern regarding the risk of anaphylactic reactions arose after a few cases during the first days of mass vaccination. Polyethylene glycol (PEG) has been suggested as the most probable culprit agent for allergic reactions.
objectiveWe describe the allergy work-up protocol implemented for the vaccination campaign in our Center, aiming to allow the greatest number of people to be vaccinated safely.
methodsThe protocol included the self-report of a history of suspected drug or vaccine allergies, and subsequent teleconsultation and allergometric tests for PEG and Polysorbate 80 (PS80). A desensitizing protocol of vaccine administration was applied to patients sensitized only to PS80, and to those with a suspect allergic reaction after the first vaccine dose.
results10.2% (414 out of 4042) of the entire vaccine population have been screened: only one patient resulted allergic to PEG and therefore excluded from the vaccination. Another patient was sensitized to PS80 only and safely vaccinated applying the desensitizing protocol. Seven subjects without a previous history of allergic disease experienced suspect hypersensitivity reactions to the first administered dose: one of them resulted allergic to PEG and was excluded from the second dose, while the others safely completed the vaccination with the desensitizing protocol.
conclusionA careful allergological risk-assessment protocol significantly reduces the number of patients who would have avoided SARS-CoV-2 vaccination for their allergies and to effectively identify and manage those rare patients with sensitization to PEGs and/or PS80.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.